Recruiting studies: First Line Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06388031 Electro-Acupuncture in Lung cancER : EALER Study
NA · 3 location(s) · Guangzhou University of Traditional Chinese Medicine · NCT07337096 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · 372 location(s) · Pfizer · NCT06758401 Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07528274 High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-g
Phase 2 · 1 location(s) · Jialei Wang · NCT06652048 Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC
Phase 2 · 7 location(s) · Advenchen Pharmaceuticals, LLC. · NCT05363280 A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGF
NA · 1 location(s) · Kunming Medical University · NCT06102928 Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3 · 1 location(s) · Peking Union Medical College Hospital · NCT06674343 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 304 location(s) · AstraZeneca · NCT06868277 PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Phase 2 · 1 location(s) · Yongchang Zhang · NCT04144569 LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
NA · 3 location(s) · Institut Curie · NCT04790682 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT07252739 Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Canc
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT07061379 Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06554613 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 312 location(s) · AstraZeneca · NCT06692738 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC Wi
Phase 3 · 286 location(s) · AstraZeneca · NCT06357533 Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3 · 2 location(s) · TYK Medicines, Inc · NCT05382728 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Sta
Phase 3 · 320 location(s) · Bristol-Myers Squibb · NCT06561386 ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno
Phase 2 · 20 location(s) · Second Xiangya Hospital of Central South University · NCT06951646 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865 Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Shanghai Cancer Hospital, China · NCT05800223 Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expressi
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07655622 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 287 location(s) · AstraZeneca · NCT06627647 Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
NA · 1 location(s) · Peking Union Medical College · NCT07247227 High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05379803 A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459 Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Phase 2 · 3 location(s) · Shanghai Chest Hospital · NCT06127303 A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell
Phase 3 · 11 location(s) · InxMed (Shanghai) Co., Ltd. · NCT07174908

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →